Aug. 5, 2026 — Bracco Group is bringing a newly authorized macrocyclic gadolinium-based contrast agent (GBCA) for contrast-enhanced magnetic resonance imaging (MRI) to Canada. Unity Health Toronto is the first hospital system in Canada to adopt its use.2
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now